跳至主要内容
临床试验/NCT01206257
NCT01206257已完成不适用

This is an International, Prospective, Non-interventional Study, Company Sponsored, Multi-center Study. Patients Undergo Coronary Angiography or PCI Procedure With Ultravist. The Primary Objective is to Evaluate the Safety and Tolerability.

Bayer0 个研究点目标入组 17,513 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
17,513
主要终点
Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization.

研究概览

简要总结

This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Female and male patients who receive Ultravist® for coronary angiography or PCI can be included in the study

排除标准

  • Patients who are or are suspected in pregnancy or nursery
  • Patients with the contraindications for Ultravist
  • Patients with the contraindications for cardiac catheterization

研究组 & 干预措施

Group 1

干预措施: Iopromide (Ultravist, BAY86-4877) (Drug)

结局指标

主要结局

Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization.

时间窗: 12 months

次要结局

  • Estimation of the image quality of Ultravist®(12 months)

研究者

发起方
Bayer
申办方类型
Industry

相似试验